

Martin Brandl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8885860/publications.pdf>

Version: 2024-02-01

109
papers

4,453
citations

81900

39
h-index

123424

61
g-index

111
all docs

111
docs citations

111
times ranked

4771
citing authors

#	ARTICLE	IF	CITATIONS
1	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106098.	4.0	29
2	Modulation of Paracellular-like Drug Transport across an Artificial Biomimetic Barrier by Osmotic Stress-Induced Liposome Shrinking. <i>Pharmaceutics</i> , 2022, 14, 721.	4.5	7
3	Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid-associated drug concentrations during biomimetic dissolution testing of supersaturating formulations. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 174, 106166.	4.0	11
4	Biopredictive capability assessment of two dissolution/permeation assays, μ FLUX [®] and PermeaLoop [®] , using supersaturating formulations of Posaconazole. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 176, 106260.	4.0	11
5	Do Phospholipids Boost or Attenuate Drug Absorption? In-Vitro and In-Vivo Evaluation of Mono- and Diacyl Phospholipid-Based Solid Dispersions of Celecoxib. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 198-207.	3.3	8
6	“Stirred not Shaken!” [™] Comparing Agitation Methods for Permeability Studies Using a Novel Type of 96-Well Sandwich-Plates. <i>Journal of Pharmaceutical Sciences</i> , 2021, , .	3.3	6
7	Identification and quantification of glucose degradation products in heat-sterilized glucose solutions for parenteral use by thin-layer chromatography. <i>PLoS ONE</i> , 2021, 16, e0253811.	2.5	4
8	Re article “Evaluation of limulus amebocyte lysate and recombinant endotoxin alternative assays for an assessment of endotoxin detection specificity”, published in <i>European Journal of Pharmaceutical Sciences</i> 159 (2021) 105716. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105877.	4.0	1
9	Application of Asymmetrical Flow Field-Flow Fractionation for Characterizing the Size and Drug Release Kinetics of Theranostic Lipid Nanovesicles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10456.	4.1	7
10	Quantification of Degradation Products Formed during Heat Sterilization of Glucose Solutions by LC-MS/MS: Impact of Autoclaving Temperature and Duration on Degradation. <i>Pharmaceutics</i> , 2021, 14, 1121.	3.8	10
11	Dissolution/Permeation of Albendazole in the Presence of Cyclodextrin and Bile Salts: A Mechanistic In-Vitro Study into Factors Governing Oral Bioavailability. <i>Journal of Pharmaceutical Sciences</i> , 2021, , .	3.3	13
12	Dissolution/permeation with PermeaLoop [®] : Experience and IVIVC exemplified by dipyridamole enabling formulations. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105532.	4.0	18
13	(Sub)micron particles forming in aqueous dispersions of amorphous solid dispersions of the poorly soluble drug ABT-199: A combined particle optical counting and field-flow fractionation study. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 154, 105497.	4.0	7
14	Drug Permeability Profiling Using the Novel Permeapad [®] 96-Well Plate. <i>Pharmaceutical Research</i> , 2020, 37, 93.	3.5	35
15	The influence of liquid intake on the performance of an amorphous solid dispersion in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 152, 296-298.	4.3	3
16	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad [®] membrane and in vivo absorption. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105452.	4.0	17
17	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 137, 104967.	4.0	222
18	High-Throughput Dissolution/Permeation Screening – A 96-Well Two-Compartment Microplate Approach. <i>Pharmaceutics</i> , 2019, 11, 227.	4.5	17

#	ARTICLE	IF	CITATIONS
19	Co-existing colloidal phases of human duodenal aspirates: Intraindividual fluctuations and interindividual variability in relation to molecular composition. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 22-29.	2.8	13
20	2. Solubility and supersaturation. , 2019, , 27-70.		2
21	A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 199-207.	4.0	23
22	Oromucosal drug delivery: Trends in in-vitro biopharmaceutical assessment of new chemical entities and formulations. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 128, 112-117.	4.0	22
23	Drug permeability profiling using cell-free permeation tools: Overview and applications. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 119, 219-233.	4.0	139
24	Co-existing colloidal phases in artificial intestinal fluids assessed by AF4/MALLS and DLS: A systematic study into cholate & (lyso-) phospholipid blends, incorporating celecoxib as a model drug. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 120, 61-72.	4.0	13
25	PermeaLoop®, a novel in vitro tool for small-scale drug-dissolution/permeation studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 156, 247-251.	2.8	27
26	Archaeal lipids in oral delivery of therapeutic peptides. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 108, 101-110.	4.0	35
27	Evaluation of a dynamic dissolution/permeation model: Mutual influence of dissolution and barrier-flux under non-steady state conditions. <i>International Journal of Pharmaceutics</i> , 2017, 522, 50-57.	5.2	24
28	Characterization of co-existing colloidal structures in fasted state simulated fluids FaSSIF: A comparative study using AF4/MALLS, DLS and DOSY. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 531-536.	2.8	15
29	Surfactants enhance recovery of poorly soluble drugs during microdialysis sampling: Implications for in vitro dissolution-/permeation-studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 586-592.	2.8	11
30	Oral bioavailability enhancement through supersaturation: an update and meta-analysis. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 403-426.	5.0	68
31	A novel microdialysis-dissolution/permeation system for testing oral dosage forms: A proof-of-concept study. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 154-163.	4.0	16
32	Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 20-27.	4.0	47
33	The use of asymmetrical flow field-flow fractionation with on-line detection in the study of drug retention within liposomal nanocarriers and drug transfer kinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 124, 157-163.	2.8	20
34	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field-Flow Fractionation/Multiangle Laser Light Scattering. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2832-2839.	3.3	36
35	Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release transfer-assay. <i>Journal of Controlled Release</i> , 2016, 232, 228-237.	9.9	25
36	Filter-extruded liposomes revisited: a study into size distributions and morphologies in relation to lipid-composition and process parameters. <i>Journal of Liposome Research</i> , 2016, 26, 11-20.	3.3	34

#	ARTICLE	IF	CITATIONS
37	A new approach for a blood-brain barrier model based on phospholipid vesicles: Membrane development and siRNA-loaded nanoparticles permeability. <i>Journal of Membrane Science</i> , 2016, 503, 8-15.	8.2	8
38	Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1113-1123.	3.3	37
39	The Effects of Temperature and Growth Phase on the Lipidomes of <i>Sulfolobus islandicus</i> and <i>Sulfolobus tokodaii</i> . <i>Life</i> , 2015, 5, 1539-1566.	2.4	38
40	Structural characterization of ether lipids from the archaeon <i>Sulfolobus islandicus</i> by high-resolution shotgun lipidomics. <i>Journal of Mass Spectrometry</i> , 2015, 50, 476-487.	1.6	35
41	Liposomes containing lipids from <i>Sulfolobus islandicus</i> withstand intestinal bile salts: An approach for oral drug delivery?. <i>International Journal of Pharmaceutics</i> , 2015, 493, 63-69.	5.2	26
42	Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 80, 89-110.	4.0	37
43	Asymmetrical flow field-flow fractionation with on-line detection for drug transfer studies: a feasibility study. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 7827-7839.	3.7	29
44	What Is the Mechanism Behind Increased Permeation Rate of a Poorly Soluble Drug from Aqueous Dispersions of an Amorphous Solid Dispersion?. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1779-1786.	3.3	91
45	Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. <i>Journal of Liposome Research</i> , 2014, 24, 323-335.	3.3	44
46	Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. <i>Journal of Liposome Research</i> , 2013, 23, 70-81.	3.3	28
47	Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations". <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 8-16.	4.0	158
48	Physicochemical characterization of liposomes after ultrasound exposure " Mechanisms of drug release. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 78-79, 118-122.	2.8	36
49	Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 233-244.	3.4	47
50	Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. <i>International Journal of Pharmaceutics</i> , 2012, 437, 288-293.	5.2	129
51	Brain delivery of camptothecin by means of solid lipid nanoparticles: Formulation design, in vitro and in vivo studies. <i>International Journal of Pharmaceutics</i> , 2012, 439, 49-62.	5.2	104
52	Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 64, 1631-1637.	2.4	13
53	The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: impact on solubility. <i>International Journal of Nanomedicine</i> , 2012, 7, 5757.	6.7	37
54	Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay. <i>International Journal of Pharmaceutics</i> , 2012, 422, 52-58.	5.2	14

#	ARTICLE	IF	CITATIONS
55	In vitro models to evaluate the permeability of poorly soluble drug entities: Challenges and perspectives. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 235-250.	4.0	113
56	Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 613-623.	4.0	51
57	Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 47, 16-20.	4.0	61
58	Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer activity: a screening method to identify maximum incorporation capacity. <i>Journal of Liposome Research</i> , 2011, 21, 272-278.	3.3	26
59	Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2011, 79, 416-422.	4.3	67
60	In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 1022-1030.	2.4	56
61	Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 380-386.	4.0	40
62	Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 318-324.	4.0	21
63	Compressibility study of quaternary phospholipid blend monolayers. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 85, 153-160.	5.0	4
64	Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. <i>International Journal of Pharmaceutics</i> , 2011, 406, 114-116.	5.2	34
65	Solubilization of ibuprofen with β -cyclodextrin derivatives: Energetic and structural studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 446-451.	2.8	56
66	Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: Development and in vitro evaluation. <i>Journal of Controlled Release</i> , 2010, 142, 319-325.	9.9	46
67	Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 40, 25-32.	4.0	96
68	In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 53, 359-365.	2.8	67
69	Liposome fractionation and size analysis by asymmetrical flow field-flow fractionation/multi-angle light scattering: influence of ionic strength and osmotic pressure of the carrier liquid. <i>Chemistry and Physics of Lipids</i> , 2010, 163, 141-147.	3.2	69
70	Vesicular Phospholipid Gels. <i>Methods in Molecular Biology</i> , 2010, 605, 205-212.	0.9	9
71	Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2010, 75, 327-333.	4.3	66
72	In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 1591-1598.	2.4	42

#	ARTICLE	IF	CITATIONS
73	Asymmetric flow field-flow fractionation of liposomes: optimization of fractionation variables. <i>Journal of Separation Science</i> , 2009, 32, 1465-1470.	2.5	49
74	Asymmetric flow field-flow fractionation of liposomes: 2. Concentration detection and adsorptive loss phenomena. <i>Journal of Separation Science</i> , 2009, 32, 3555-3561.	2.5	37
75	Altered Activity and Physicochemical Properties of Short Cationic Antimicrobial Peptides by Incorporation of Arginine Analogues. <i>Molecular Pharmaceutics</i> , 2009, 6, 996-1005.	4.6	45
76	Drug permeability across a phospholipid vesicle-based barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 34, 173-180.	4.0	48
77	Vesicular Phospholipid Gels: A Technology Platform. <i>Journal of Liposome Research</i> , 2007, 17, 15-26.	3.3	28
78	Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 30, 324-332.	4.0	39
79	Liposome Size Analysis by Dynamic/Static Light Scattering upon Size Exclusion-/Field Flow-Fractionation. <i>Journal of Nanoscience and Nanotechnology</i> , 2006, 6, 3025-3031.	0.9	69
80	Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 80-90.	4.0	148
81	Drug permeability across a phospholipid vesicle-based barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 28, 336-343.	4.0	67
82	Vesicular Phospholipid Gels. , 2006, , 241-260.		3
83	Camptothecin-catalyzed phospholipid hydrolysis in liposomes. <i>International Journal of Pharmaceutics</i> , 2005, 288, 73-80.	5.2	24
84	Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetorelix. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 59, 439-448.	4.3	29
85	Adsorption of the decapeptide Cetorelix depends both on the composition of dissolution medium and the type of solid surface. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 191-196.	4.0	35
86	A method to determine the incorporation capacity of camptothecin in liposomes. <i>AAPS PharmSciTech</i> , 2004, 5, 30-37.	3.3	26
87	Effect of hydroxypropyl- β -cyclodextrin-complexation and pH on solubility of camptothecin. <i>International Journal of Pharmaceutics</i> , 2004, 284, 61-68.	5.2	48
88	Development and validation of a HPLC method for routine quantification of the decapeptide Cetorelix in liposome dispersions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 963-969.	2.8	17
89	Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. <i>Anti-Cancer Drugs</i> , 2004, 15, 899-906.	1.4	19
90	Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions. <i>AAPS PharmSciTech</i> , 2003, 4, 62-70.	3.3	23

#	ARTICLE	IF	CITATIONS
91	Quantification of various phosphatidylcholines in liposomes by enzymatic assay. AAPS PharmSciTech, 2003, 4, 500-505.	3.3	25
92	5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. International Journal of Pharmaceutics, 2003, 256, 123-131.	5.2	92
93	Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anti-Cancer Drugs, 2002, 13, 797-805.	1.4	15
94	Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemotherapy and Pharmacology, 2002, 49, 356-366.	2.3	72
95	Determination of the size distribution of liposomes by SEC fractionation, and PCS analysis and enzymatic assay of lipid content. AAPS PharmSciTech, 2002, 3, 9-15.	3.3	20
96	Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. International Journal of Pharmaceutics, 2001, 223, 55-68.	5.2	207
97	Steam sterilisation of vesicular phospholipid gels. International Journal of Pharmaceutics, 2001, 217, 161-172.	5.2	42
98	Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids. International Journal of Pharmaceutics, 2000, 206, 43-53.	5.2	20
99	Erosion and controlled release properties of semisolid vesicular phospholipid dispersions. Journal of Controlled Release, 1998, 55, 261-270.	9.9	31
100	Preparation and characterization of semi-solid phospholipid dispersions and dilutions thereof. International Journal of Pharmaceutics, 1998, 170, 187-199.	5.2	43
101	Morphology of semisolid aqueous phosphatidylcholine dispersions, a freeze fracture electron microscopy study. Chemistry and Physics of Lipids, 1997, 87, 65-72.	3.2	38
102	Biodistribution and Computed tomography Blood-Pool Imaging Properties of Polyethylene Glycol-Coated Iopromide-Carrying Liposomes. Investigative Radiology, 1997, 32, 44-50.	6.2	51
103	Liposomes with nifedipine and nifedipine-cyclodextrin complex: calorimetric and plasma stability comparison. European Journal of Pharmaceutical Sciences, 1996, 4, 359-366.	4.0	45
104	Surface modification of continuously extruded contrast-carrying liposomes: Effect on their physical properties. International Journal of Pharmaceutics, 1996, 132, 9-21.	5.2	24
105	Generation of contrast-carrying liposomes of defined size with a new continuous high pressure extrusion method. International Journal of Pharmaceutics, 1995, 117, 1-12.	5.2	53
106	Detection of Lipopolysaccharides in Phospholipids and Liposomes Using the Limulus Test. Journal of Liposome Research, 1995, 5, 109-116.	3.3	11
107	Entrapment of haemoglobin into liposomes by the dehydration-rehydration method: vesicle characterization and in vivo behaviour. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1196, 65-75.	2.6	24
108	Acute toxicity and depression of phagocytosis in vivo by liposomes: Influence of lysophosphatidylcholine. Life Sciences, 1994, 56, 99-106.	4.3	8

#	ARTICLE	IF	CITATIONS
109	Preparation of liposomes using a Mini-Lab 8.30 H high-pressure homogenizer. International Journal of Pharmaceutics, 1993, 91, 69-74.	5.2	30